Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06432673
Status:
COMPLETED
Last Update Posted:
2024-07-01
First Post:
2024-05-07
Brief Title:
The Attractive 2 Trial - Pharmacokinetics of ATR-258 Oral Capsule vs Oral Solution Formulations in Healthy Volunteers
Sponsor:
Atrogi AB
Organization:
Atrogi AB
Study Overview
Official Title:
The Attractive 2 Trial - An Open-label Randomised 2-period Cross-over Trial to Assess the Pharmacokinetics of ATR-258 Oral Capsule vs Oral Solution Formulations in Healthy Volunteers
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Attractive 2
Brief Summary:
This is a single-centre open-label randomised 2-period cross-over Phase 1 comparative trial to assess the ATR-258 pharmacokinetic PK parameters of an oral capsule formulation in comparison with an oral solution formulation both given as single doses to healthy volunteers The order of treatment ie the treatment sequence capsule - solution or solution - capsule will be randomised
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-508797-28-00 | CTIS | None | None |